BETA: Please send your feedback!
Workday
WDAY:NAS
Information Technology Services
$43.42bn
LARGE cap
$192.13
(-1.24%)
0.20%
since start of 2019
-91.55
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Pharmaceuticals: Other
Founded 2012
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in identifying, developing and commercializing novel drugs to address unmet needs in dermatology. It also pursues the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
website
Headquarters
Executives
| Name | Title | Gender |
| Mark S. Peek | Co-President | Male |
| Phil Wilmington | Co-President | Male |
| Aneel Bhusri, MBA | Chief Executive Officer & Director | Male |
| Stan Swete | Chief Technology Officer | Male |
| Dave Duffield, MBA | Chairman | Male |
| Ashley D. Goldsmith, MBA | Chief People Officer | Female |
| Jim Shaughnessy | Secretary, Senior Vice President & General Counsel | Male |
| Robynne D. Sisco, MBA | Chief Financial Officer | Female |
| Diana L. McKenzie | Chief Information Officer | Female |
| James Redfern | VP-Corporate Development & Head-Investor Relations | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
Aclaris Therapeutics - Competitors and Related Companies
How Aclaris Therapeutics stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Aclaris Therapeutics
ACRS:NAS
Pharmaceuticals: Other
$43.85mm
SMALL cap
$1.06
(-0.03%)
-0.89%
since start of 2019
-0.25
Loading…